Celling Biosciences buys ThermiGen assets.

Almirall has sold its ThermiGen assets to Celling Biosciences. The companies expect to close the deal on 29th March, which will see Celling Biosciences taking control of Thermi, its 94 employees and users who number over 2,000.
Kevin Dunworth, Celling Biosciences chief executive officer, said: “We are excited about the acquisition announced today and the expansion of our portfolio with ThermiGen’s leading energy-based technology. Acquiring this technology will allow Celling to combine their unique cellular therapy devices with the existing ThermiGen technology to offer physicians a unique scientific approach to treat their patience.”
Peter Guenter, Almirall chief executive officer, said: “Almirall continues to refocus its business towards medical dermatology. With this divestment, Almirall completes its strategic realignment and puts Thermi business in very good hands to capture the potential of the new Arvati innovative platform.”